Tafamidis meglumine, 1g

Tafamidis meglumine (Vyndaqel, Fx-1006A) stabilizes the tetrameric structure of transthyretin (TTR) by binding to thyroxine-binding sites. Tafamidis meglumine treats transthyretin familial amyloid polyneuropathies (TTR-FAP), a condition characterized by neurological damage from TTR amyloidosis, by preventing the misfolding and aggregation of transthyretin (TTR) into amyloid fibrils.